NoneSmall-Cell Lung Cancer

Clarify the real-world efficacy and safety of second line Toripalimab advanced none small-cell lung cancer in a retrospective multi center trial.

by

Real-World Efficacy of Second-Line Toripalimab in Patients With Advanced NoneSmall-Cell Lung Cancer. Clarify the real-world efficacy and safety of second line Toripalimab advanced nonesmall-cell lung cancer in a retrospective multi center trial. Non adenocarcinoma and a large number of metastatic sites correlated with poor progression-free sur vival (PFS). PFS and overall survival (OS) were longer … Read more

Clarify the real-world efficacy and safety of second-line Toripalimab with advanced nonesmall-cell lung cancer in a retrospective multicenter trial.

by

Real-World Efficacy of Second-Line Toripalimab •Clarify the real-world efficacy and safety of second-line Toripalimab with advanced nonesmall-cell lung cancer in a retrospective multicenter trial. •Nonadenocarcinoma and a large number of metastatic sites correlated with poor progression-free sur vival (PFS). •PFS and overall survival (OS) were longer in patients with pembrolizumab-related adverse events;however, PFS and OS … Read more